Biyang Xu, Melissa Lowe, Vladislav Levchenko, Mark N. Morales, Christine A. Klemens, Christopher T. Banek, Alexander Staruschenko
{"title":"Effect of Renal Denervation on Early and Late Stages of Diabetic Nephropathy","authors":"Biyang Xu, Melissa Lowe, Vladislav Levchenko, Mark N. Morales, Christine A. Klemens, Christopher T. Banek, Alexander Staruschenko","doi":"10.1096/fj.202501453R","DOIUrl":null,"url":null,"abstract":"<p>Diabetic kidney disease (DKD) is a major driver of morbidity and mortality worldwide. Although the FDA has recently approved renal denervation (RDNx) to treat hypertension, contradictory findings have been reported on the effect of RDNx on the progression of DKD in type 2 diabetes. Here, we used type 2 diabetic nephropathy (T2DN) rats, a well-established non-obese model that mimics key features in human DKD, to evaluate the effect of RDNx on the progression of DKD in the early and late stages of diabetic nephropathy. Results indicate that RDNx lowers mean arterial pressure in the early but not late stage of DKD without improving glycemic control or renal function, which may suggest that the effect of RDNx on type 2 diabetes is stage-dependent, emphasizing the importance of timing when considering RDNx as a potential treatment for DKD.</p>","PeriodicalId":50455,"journal":{"name":"The FASEB Journal","volume":"39 13","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1096/fj.202501453R","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The FASEB Journal","FirstCategoryId":"99","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1096/fj.202501453R","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Diabetic kidney disease (DKD) is a major driver of morbidity and mortality worldwide. Although the FDA has recently approved renal denervation (RDNx) to treat hypertension, contradictory findings have been reported on the effect of RDNx on the progression of DKD in type 2 diabetes. Here, we used type 2 diabetic nephropathy (T2DN) rats, a well-established non-obese model that mimics key features in human DKD, to evaluate the effect of RDNx on the progression of DKD in the early and late stages of diabetic nephropathy. Results indicate that RDNx lowers mean arterial pressure in the early but not late stage of DKD without improving glycemic control or renal function, which may suggest that the effect of RDNx on type 2 diabetes is stage-dependent, emphasizing the importance of timing when considering RDNx as a potential treatment for DKD.
期刊介绍：
The FASEB Journal publishes international, transdisciplinary research covering all fields of biology at every level of organization: atomic, molecular, cell, tissue, organ, organismic and population. While the journal strives to include research that cuts across the biological sciences, it also considers submissions that lie within one field, but may have implications for other fields as well. The journal seeks to publish basic and translational research, but also welcomes reports of pre-clinical and early clinical research. In addition to research, review, and hypothesis submissions, The FASEB Journal also seeks perspectives, commentaries, book reviews, and similar content related to the life sciences in its Up Front section.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
